Literature DB >> 1806481

Effects of growth hormone on glucose metabolism.

N Møller1, J O Jørgensen, N Abildgård, L Orskov, O Schmitz, J S Christiansen.   

Abstract

Growth hormone (GH) counteracts in general the effects of insulin on glucose and lipid metabolism, but shares protein anabolic properties with insulin. Under physiological circumstances GH does not affect total glucose turnover directly. There is however evidence that GH acutely decreases glucose oxidation (secondary to an increase in lipid oxidation) and suppresses muscle uptake of glucose, suggesting that GH redistributes glucose fluxes into a non-oxidative pathway, which could be a build up of glycogen depots through gluconeogenesis. Since GH secretion is inhibited in the fed state these actions are mainly important in the postprandial or fasting state. Under pathological conditions of GH excess (e.g. acromegaly, poorly controlled tp. 1 diabetes or high dose GH treatment) the diabetogenic actions of GH become apparent. In these patients increased endogenous glucose production, decreased muscle glucose uptake and rising blood glucose levels are observed. In patients with intact beta-cell function these changes are counterbalanced by hyperinsulinemia--such hyperinsulinemia may in the long term induce increased cardiovascular morbidity and mortality ('Reavens syndrome X'). When stimulated with insulin these patients exhibit insulin resistance at the liver, in adipose tissue and in muscle. Few elaborate studies on the effects of GH on glucose metabolism in GH deficient patients have been conducted. These patients are hypersensitive to the actions of insulin on glucose metabolism and there is some evidence that when GH initially is given to such patients in the GH deprived state, paradox insulin-like effects of GH may be observed. Whether this may relate to increased activity of insulin-like growth factors is unsettled.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1806481

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  19 in total

1.  Preoperative octreotide therapy and surgery in acromegaly: associations between glucose homeostasis and treatment response.

Authors:  R Helseth; S M Carlsen; J Bollerslev; J Svartberg; M Øksnes; S Skeie; S L Fougner
Journal:  Endocrine       Date:  2015-07-16       Impact factor: 3.633

2.  Glucose status in patients with acromegaly receiving primary treatment with the somatostatin analog lanreotide.

Authors:  Elisabeth Couture; Vanina Bongard; Jean-Christophe Maiza; Antoine Bennet; Philippe Caron
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

Review 3.  Acromegaly: clinical features at diagnosis.

Authors:  Lucio Vilar; Clarice Freitas Vilar; Ruy Lyra; Raissa Lyra; Luciana A Naves
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

4.  A rare case of adulthood-onset growth hormone deficiency presenting as sporadic, symptomatic hypoglycemia.

Authors:  A Pia; A Piovesan; F Tassone; P Razzore; G Visconti; G Magro; F Cesario; M Terzolo; G Borretta
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

5.  The GH/IGF-1 Axis and Heart Failure.

Authors:  Graziella Castellano; Flora Affuso; Pasquale Di Conza; Serafino Fazio
Journal:  Curr Cardiol Rev       Date:  2009-08

6.  Expression of an ovine growth hormone transgene in mice increases arachidonic acid in cellular membranes.

Authors:  J D Murray; A M Oberbauer; K R Sharp; J B German
Journal:  Transgenic Res       Date:  1994-07       Impact factor: 2.788

Review 7.  Roles of insulin-like growth factor-I and growth hormone in mediating insulin resistance in acromegaly.

Authors:  David Robert Clemmons
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

8.  Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice.

Authors:  Shoshana Yakar; Jennifer Setser; Hong Zhao; Bethel Stannard; Martin Haluzik; Vaida Glatt; Mary L Bouxsein; John J Kopchick; Derek LeRoith
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

9.  Management of type 2 diabetes mellitus associated with pituitary gigantism.

Authors:  Omar Ali; Swati Banerjee; Daniel F Kelly; Phillip D K Lee
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

Review 10.  Circadian regulation of glucose, lipid, and energy metabolism in humans.

Authors:  Eleonora Poggiogalle; Humaira Jamshed; Courtney M Peterson
Journal:  Metabolism       Date:  2018-01-09       Impact factor: 8.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.